Cardior: Novo shells out $1.1bn to buy Cardior to expand cardiovascular pipeline
Novo Nordisk will pay up to $1.1bn in upfront and milestone-based payments, with the acquisition expected to close in Q2 2024.
Read full article »
Cardior is a Germany-based biopharmaceutical company that researches and develops RNA-dependent therapies for the treatment of heart diseases.
Read more